Revenue by Product | Investor Relations | CHUGAI PHARMACEUTICAL CO., LTD.

(Billions of Yen)

					2007	2008	2009	2010	2011
Sales					332.9	321.8	419.1	375.6	363.6
	Excl.Tamiflu®				294.3	313.4	342.9	357.4	354.9
		Domestic			263.1	279.9	309.3	324.4	315.3
			Oncology field		74.0	102.3	123.7	141.2	141.9
				Avastin®	3.5	20.1	34.9	52.6	56.4
				Herceptin®	16.1	23.7	29.7	25.3	25.9
				Rituxan®	18.6	20.5	21.1	23.0	22.9
				Xeloda®	2.7	4.8	6.6	10.7	10.0
				Neutrogin®	12.6	12.0	11.3	10.4	9.4
				Tarceva®	0.2	4.5	5.8	7.9	8.3
				Femara®	1.0	1.7	2.4	3.2	3.6
				Kytril®	13.6	10.9	8.6	5.5	3.4
				Other products	5.6	4.1	3.3	2.5	2.1
			Bone and joint diseases field		46.6	50.0	57.6	62.6	66.2
				Evista®	16.0	16.5	17.9	18.7	18.5
				Actemra®	0.5	3.4	8.4	14.1	17.5
				Suvenyl®	11.0	12.0	13.7	13.6	13.0
				Alfarol®	14.3	13.7	13.6	12.3	11.2
				Edirol®	-	-	-	-	1.3
				Other products	4.8	4.5	3.9	4.0	4.6
			Renal diseases field		69.6	61.3	61.0	57.4	50.7
				Epogin®	54.8	44.9	44.4	40.0	28.8
				Mircera®	-	-	-	-	5.9
				Oxarol®	8.7	10.0	10.6	12.0	12.2
				Renagel®	5.6	5.7	5.3	4.9	3.1
				Other products	0.5	0.7	0.7	0.5	0.7
			Transplant, Immunology & Infectious diseases field		17.7	24.0	26.2	25.8	22.8
				Pegasys®	6.3	9.7	11.1	10.5	8.3
				Copegus®	2.0	4.2	4.9	4.5	3.3
				CellCept®	3.5	4.0	4.4	5.2	5.7
				Rocephin®	5.7	5.9	5.5	5.4	5.1
				Other products	0.3	0.3	0.3	0.3	0.3
			Others field		55.1	42.3	40.9	37.4	33.8
				Sigmart®	15.2	15.0	14.7	13.0	11.1
				Other products	40.0	27.3	26.3	24.4	22.6
		Overseas			31.2	33.5	33.6	33.0	39.6
				Actemra®	-	3.8	8.9	12.7	20.5
				Neutrogin®	26.6	25.9	21.3	17.0	15.6
				Sigmart®	2.8	2.0	1.9	2.2	2.1
				Other products	1.9	1.7	1.5	1.2	1.4
	Tamiflu®				38.7	8.4	76.2	18.2	8.7
		Ordinary sales			10.2	7.1	36.2	1.6	5.4
		Govt. stockpile etc.			28.5	1.3	40.0	16.6	3.3
Other operating revenues					11.9	5.1	9.8	3.9	9.9
Revenues (total)					344.8	326.9	428.9	379.5	373.5
		Domestic			308.4	293.1	392.6	342.9	327.9
		Overseas			36.4	33.8	36.4	36.6	45.6